A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

← catalyst calendar

NCT06163326 · readout in 224 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

394actual

Sites

Countries

Australia, Bulgaria, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-01-19

actual

When the study began enrolling

Primary completion

2027-03-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-03-31

estimated

The whole study's end, after follow-up

First posted

2023-12-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Vitiligo

Interventions

Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation

measured Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

Incidence of clinically significant laboratory abnormalities

measured Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

Publications

PMID 42171987 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed